Advertisement

Initial Symptomatic Treatment of Parkinson’s Disease

  • J. Eric Ahlskog
Part of the Current Clinical Practice book series (CCP)

Abstract

Treatment of the patient with recent-onset Parkinson’ s disease (PD) is often a very gratifying experience. Although we do not have medications with proven efficacy for slowing disease progression, we do have good drugs for symptomatic treatment. The physician’s role is to keep patients within the mainstream of life. Patients whose lives are compromised obviously need to be treated, whereas others with more minor symptoms (e.g., isolated tremor) may not require therapy. The patient should participate in the decision. Some symptoms and signs that the physician may regard as minor may be troublesome to the patient. For example, someone in the public eye might be quite disabled by parkinsonian tremor that might not bother others. Clearly, however, persons curtailing their activities because of parkinsonism should be treated with adequate medications and doses.

Keywords

Dopamine Agonist Multiple System Atrophy Levodopa Therapy Motor Complication Large Neutral Amino Acid 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Selected Reading

  1. Adler CH, Sethi KD, Hauser RA, Davis TL, Hammerstad JP, Bertoni J, Taylor RL, Sanchez-Ramos J, O’Brien CF. Ropinirole for the treatment of early Parkinson’s disease. The Ropinirole Study Group. Neurology 1997; 49: 393–399.PubMedCrossRefGoogle Scholar
  2. Ahlskog JE. Treatment of early Parkinson’s disease: are complicated strategies justified? Mayo Clin Proc1996; 71: 659–670.PubMedCrossRefGoogle Scholar
  3. Block G, Liss C, Reines S, Irr J, Nibbelink D, The CR First Study Group. Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson’s disease. A multicenter 5-year study. Eur Neurol1997; 37: 23–27.PubMedCrossRefGoogle Scholar
  4. Olanow CW, Koller WC. An algorithm (decision tree) for the management of Parkinson’s disease: treatment guidelines. American Academy of Neurology. Neurology 1998; 50 (Suppl 3): S1–57.PubMedCrossRefGoogle Scholar
  5. Quinn N, Critchley P, Marsden CD. Young onset Parkinson’s disease. Mov Disord1987; 2:73–91.CrossRefGoogle Scholar
  6. Shannon KM, Bennett JP Jr, Friedman JH for the Pramipexole Study Group. Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson’s disease. Neurology 1997; 49: 724–728.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2000

Authors and Affiliations

  • J. Eric Ahlskog

There are no affiliations available

Personalised recommendations